• Regeneus Ltd IPO Information

    Regeneus publishes updated HiQCell Joint Registry Interim Report

    March 2014: Regeneus have published an updated HiQCell Joint Registry Interim Report, detailing further results from its ethics approved joint registry used to track the safety and effectiveness of HiQCell in the treatment of osteoarthritis.

    Download a copy of the updated
    HiQCell Joint Registry Interim Report »

  • Clinic specializing in Regeneus stem cell therapy

    Positive Biomarker Results in World-First Stem Cell Knee Osteoarthritis Trial

    - MRI shows HiQCell therapy has potential disease modifying effect by slowing cartilage degradation;

    - Discovery that biomarker MIF can be used to accurately measure the anti-inflammatory effects of stem cell treatments.

    View the Press Release here »

  • Injection of the HiQCell stem cell therapy

    Stem cell therapy comes to John Flynn Private Hospital in the Gold Coast

    Regeneus has expanded its footprint from the Sydney facilities offering HiQCell and has established a new cell processing laboratory at John Flynn Private Hospital in the Gold Coast allowing Queensland patients closer access to the treatment.

    More »

  • CryoShot - an allogeneic stem cell therapy

    Off-the-shelf stem cell therapy to treat canine and equine osteoarthritis

    CryoShot is an allogeneic cell-based product derived from regenerative cells in adipose tissue including mesenchymal stem cells and adipocytes for the canine and equine markets.

    More »

  • Cryogenic cellular therapies storage

    Freezing of stem cells for osteoarthritis now available

    Regenerative medicine company, Regeneus, and cryogenic storage specialists, Cryosite Limited, have completed the development of a procedure for storing a patient's regenerative stem cells from fat.

    More »

  • Stem cell therapy specialist at work

    Regeneus validates therapeutic benefits of stem cell secretions platform

    Regeneus completed a successful trial validating the efficacy of the company's adipose (fat) derived stem cell secretion therapy using a well-established mouse model for rheumatoid arthritis.

    More »

Improving quality of life through innovative cellular therapies

Regeneus is excited to announce that over 450 patients have now been commercially treated with our HiQCell® stem cell therapy.

These patients are captured within our Patient Joint Registry which allows us to continue to capture long-term data so that we can learn more of the treatment effects of HiQCell.

More about HiQCell stem cell therapy »

At Regeneus, we focus on improving quality of life through cellular therapies.

We develop and commercialise proprietary technologies for the preparation of autologous point-of-care and off-the-shelf cell therapies for the treatment of musculoskeletal and other inflammatory conditions in humans and animals.

More about Regeneus »

Our Therapies

Human Health

Animal Health

CryoShot is an off-the-shelf stem cell therapy used for the treatment of conditions such as osteoarthritis in dogs and horses. More » about CryoShot